380 related articles for article (PubMed ID: 32700868)
1. Treatment of Helicobacter pylori infection: a clinical practice update.
Zagari RM; Frazzoni L; Marasco G; Fuccio L; Bazzoli F
Minerva Med; 2021 Apr; 112(2):281-287. PubMed ID: 32700868
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
3. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
4. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Chey WD; Leontiadis GI; Howden CW; Moss SF
Am J Gastroenterol; 2017 Feb; 112(2):212-239. PubMed ID: 28071659
[TBL] [Abstract][Full Text] [Related]
5. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Fallone CA; Moss SF; Malfertheiner P
Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990
[TBL] [Abstract][Full Text] [Related]
6. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
7. Second-line rescue treatment of
Lin TF; Hsu PI
World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori treatment: Still a work in progress.
Senatore FJ; Wilmot J; Birk JW
Postgrad Med; 2016 Jan; 128(1):152-7. PubMed ID: 26490697
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
11. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
Valle Muñoz J; Muñoz Gómez P; Sierra Bernal C; de Andrés E; Gómez Hernando C; Gómez Rodríguez R
Rev Esp Enferm Dig; 2019 Sep; 111(9):655-661. PubMed ID: 31345044
[TBL] [Abstract][Full Text] [Related]
12. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
13. [Helicobacter pylori-associated diseases].
Gisbert JP
Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():39-48. PubMed ID: 26520195
[TBL] [Abstract][Full Text] [Related]
14. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
15. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Zhang M; Chen CY; Wang XT; Lyu B
Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
[No Abstract] [Full Text] [Related]
16. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Marin AC; McNicholl AG; Gisbert JP
Expert Opin Pharmacother; 2013 May; 14(7):843-61. PubMed ID: 23537368
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
Xin Y; Manson J; Govan L; Harbour R; Bennison J; Watson E; Wu O
BMC Gastroenterol; 2016 Jul; 16(1):80. PubMed ID: 27460211
[TBL] [Abstract][Full Text] [Related]
18. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
Gisbert JP; Calvet X
Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241
[TBL] [Abstract][Full Text] [Related]
19. Practical Aspects in Choosing a Helicobacter pylori Therapy.
Molina-Infante J; Shiotani A
Gastroenterol Clin North Am; 2015 Sep; 44(3):519-35. PubMed ID: 26314666
[TBL] [Abstract][Full Text] [Related]
20. Role of Bismuth in the Eradication of Helicobacter pylori.
Alkim H; Koksal AR; Boga S; Sen I; Alkim C
Am J Ther; 2017; 24(6):e751-e757. PubMed ID: 26808355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
